BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Cardinal Health announced that it has entered into a strategic collaboration with Palantir Technologies Inc., a leading builder of operating systems for the modern enterprise, to design a solution that will give health systems and hospitals dynamic purchase decision insights in order to quickly improve their bottom line.

Syros Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS).

Akeso, Inc. announced the Hart-Scott-Rodino (HSR) Act filing has cleared for the previously announced collaboration and license agreement between Akeso and Summit Therapeutics (the “Summit”) for the breakthrough bispecific antibody, Ivonescimab (PD-1/VEGF). Akeso had received the first tranche of the upfront payment of US$300 million.

Longevity Biomedical, Inc. and Denali Capital Acquisition Corp. today announced that they have entered into a definitive business combination agreement (the “BCA”).

CytomX Therapeutics, Inc. today announced that it achieved a clinical candidate milestone under its TCB agreement with Astellas.

Medicenna Therapeutics Corp. today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights.

Monopar Therapeutics Inc. today announced it is planning to report over the next two months (1) the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, (2) clinical data from its camsirubicin Phase 1b trial, and (3) a preclinical progress update on its MNPR-101 RIT program.

Apogee Therapeutics, Inc. today announced the appointment of Jane Pritchett Henderson as Chief Financial Officer.

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi ® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.